JPS6270318A - Hemostatic and wound-protecting agent - Google Patents

Abstract

PURPOSE:To provide the titled agent exhibiting excellent hemostatic and wound- protecting activities and containing sodium polyacrylate powder having a specific average particle diameter. CONSTITUTION:The objective hemostatic and wound-protecting agent can be produced by mixing (A) powder of sodium polyacrylate having an average particle diameter of <=140mum, preferably 30-3mum (PANA which may be partially crosslinked. The average molecular weight of the polymer is >=500,000, preferably >=1,500,000 and a substitution degree of sodium is 20-100%, preferably 40-100%) and (B) a medicine useful for hemostasis and the remedy of wound (e.g. an antibacterial agent such as tetracycline, an anti-inflammatory agent such as sulpyrine, local anesthetic such as lidocaine hydrochloride) to (C) a substrate for external use. The amount of the component B is 0.01-6% for antibacterial agent, 1-40% for anti-inflammatory agent and 0.01-4% for local anesthetic based on the whole drug preparation. The agent may be added further with a water-soluble natural polymer such as collagen, gelatin, etc.

Description

[Detailed description of the invention] [Industrial application field] The present invention relates to hemostatic and wound protection agents.

[Conventional technology]

Conventionally, as a preparation for the purpose of hemostasis and wound protection, for example, a powder consisting of horse starch, lactose, and fradiomycin sulfate is known.

[Problems to be solved by the invention]

However, these preparations have drawbacks such as insufficient hemostatic properties and insufficient wound protection.

[Failure to solve the problem]

As a result of various studies, the present inventors have discovered that sodium polyacrylate (hereinafter referred to as PAN Aj) powder exhibits excellent hemostasis and wound protection effects.

The present invention has been completed based on the above findings.

PANA used in the present invention may be partially crosslinked, and has an average molecular weight of 500,000 or more, more preferably 1,500,000 or more.

Further, the degree of substitution of sodium ions is 20 to 100 degrees, more preferably 40 to 100 degrees.

The average particle size of the PANA powder is 140 μm or less, preferably 100 μm or less, and more preferably about 30 μm to 3 μm (microscopic method).

The hemostasis and wound protection agent of the present invention may contain a drug useful for promoting wound healing.

Examples of drugs include tetrazycline, benzylpenicillin, ampicillin, amoxicillin, cephalothin sodium, erythromycin, tetracycline hydrochloride, fradiomizone sulfate, gentamicin sulfate, sulfathiazole, chlorhexidine, temerosal, iodoform, boric acid, paraformaldehyde, chloride. Antibacterial agents such as dequalinium, povidone-iodine, survirin, antipyrine, aspirin, phenylbutacin.

Examples include anti-inflammatory agents such as mefenamic acid, diclofenac sodium, ketoprofen, ibuprofen, dexamethasone, triamcinolone acetonide, and prostaglandins, and local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, and lidocaine hydrochloride. The amount added is 2 to 30% of the total amount of the preparation.1 In the case of local anesthetics, it is 0.0%.
It is about 1 to 4%, preferably about 0.1 to 2%.

The preparation of the present invention can be applied directly to the wound surface in the form of a powder, an ointment, or a sheet-like preparation prepared by coating them on a sheet, but a powder is preferable.

In the case of a powder, PANA powder may be used as a powder, but usually PANA powder is used together with a drug, if desired, as a base for a powder for external use, such as starch.

It is added to the powder of waxes such as lactose, talc, kaolin, silica, salivary lead oxide, Avicel, Erosil, smectite, and beeswax, mixed uniformly, and made into a single powder without being molded and crushed.

The amount of the base used is 80% or less, preferably 50 to 5%, based on the total amount of the preparation.

Ointments are manufactured by adding powders such as PA, NA powder, if desired, along with drugs to an ointment base and mixing uniformly in a conventional manner. The ointment base used here is preferably an oily base such as various vegetable oils, fatty acid triglycerides, Plastibase, and petrolatum. The amount of PANAO in this preparation is 5-80% of the total amount of the preparation,
More preferably it is 10 to 65%.

Further, other additives may be added to the hemostasis and wound protection agent of the present invention. Examples of additives include collagen,
Examples include natural water-soluble polymers such as gelatin.

The amount of these added is 30% or less, more preferably 20% or less based on PANA.

〔Effect of the invention〕

One of the products of the present invention or a control product was applied to 10 volunteers who had sustained bleeding cuts or abrasions on their hands and feet, and the state of hemostasis and the state of fixation and repair of the wounds were observed.

The samples and experimental methods are as follows.

(1) Sample: Table 1 Table 1 (2) Experimental method In the case of a powder sample, it was sprinkled to cover the entire wound surface, gauze was applied over it, and a bandage was applied. In the case of ointment, it was applied thinly to gauze in advance and applied to the wound surface.

12 hours after applying each sample to the wound surface, the degree of bleeding and blood adhesion to the gauze is used as a guideline for the hemostatic effect.
In addition, the state of wound recovery was visually observed. The ratings were as follows.

(Blood adhesion to the gauze, extent of dirt) is mostly adhesion, no dirt - 2 Slight adhesion, dirt... - - mountain...・+1 attached,
Dirt...Mountains, rivers...
0 too much adhesion, a little bit of dirt...Y/N-1 adhesion,
Very dirty・・・・・・・・・・・・－・River...
・-2 (state of wound recovery) The wound surface or opening dries quickly, and force skin formation occurs quickly +1 (3
) Results and Discussion The results are shown in Table 2. Symptoms vary considerably between volunteers, so it is difficult to compare the effects of administration under the same conditions, but when comparing patients with similar injuries,
Those who received the inventive product experienced less bleeding and the wound dried more quickly.

Force skin formation is promoted. This shows that the formulation of the present invention exhibits excellent hemostasis and wound protection effects.

Table 2 [Example] Example 1 Powder 60 of sodium polyacrylate with an average molecular weight of 5.4 million, an average particle diameter of 1 μm, and a degree of sodium substitution of 100%.
10ii' of powder was uniformly mixed with 20 parts of sufficiently dried horse starch, 19 parts of lactose, and 1 part of sulfuric acid aradiomycif, and filled in a polyethylene bottle. do.

Example 2 50 parts of sodium polyacrylate powder with an average molecular weight of 1.8 million and an average particle size of 5 μm and a degree of sodium substitution of 80%, 20 parts of gelatin powder with an average particle size of 15 μm, and 10 parts of sufficiently dried corn starch.

10 homogeneously mixed powder consisting of 3 parts fibrinogen and 17 parts lactose? Fill a polyethylene bottle.

Example 3 Average molecular weight 8.1 million, average particle size 4.1 μm.

A polyethylene bottle is filled with 10 liters of finely powdered sodium polyacrylate powder with a degree of sodium substitution of +00.

Patent applicant: Nippon Kayaku Co., Ltd. 19 completed-

Claims (1)

[Claims] Hemostatic and wound protection agent containing sodium polyacrylate powder with an average particle size of 140 μm or less